Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06207903
Starting soon Observational

Navigating the Clinical Research Process for Mild Cognitive Impairment

NCT06207903 · tracked via the Priya Life Science USA tracker
Sponsor
Power Life Sciences Inc
Phase
Observational
Started
2025-02
Last updated
2024-01-17

Condition(s) studied

Mild Cognitive Impairment

Study summary

Participation in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This trial will admit a wide range of data on the clinical trial experience of mild cognitive impairment patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future mild cognitive impairment patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of mild cognitive impairment * Participant must be 18 years of age or older * Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study. Exclusion Criteria: * Pregnant or lactating woman * Participant is actively receiving study therapy in another * Inability to provide written informed consent

Primary outcome measure(s)

  • Rate of patients who decide to enroll in a mild cognitive impairment clinical research. — 3 months
  • Number of mild cognitive impairment study participants who remain in clinical study until completion. — 12 months

Trial sites (1)

FacilityCityRegionStatus
Power Life Sciences San Francisco California

More Power Life Sciences Inc. trials in the USA

Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study Starting soon
Revealing Engagement Patterns Among Hepatic Encephalopathy Patients Starting soon
Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research Starting soon
Assessing Patient Engagement in Keratoconus Clinical Research Starting soon
Exploring Acne Treatments Through Clinical Research Participation Starting soon

Other trials for the same condition

A Novel Computer-Based Functional Skills Assessment and Training Program Active, not recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia Recruiting
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking) Active, not recruiting
Home Sleep Therapy for Older Adults With MCI Recruiting
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06207903 on ClinicalTrials.gov ↗ ← All trials in the USA